LEXINGTON, Mass., Feb. 9, 2021 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced ...
Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study. This is an ASCO Meeting Abstract from the ...
- Additional data to be presented in oral presentation and poster session at the European Hematology Association 2021 Virtual Congress (EHA); along with company-hosted virtual KOL event on June 11, ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to CA-4948 for treatment of acute myeloid leukemia and myelodysplastic ...
LEXINGTON, Mass., April 19, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, is pleased to ...
First-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress. Background: Activated NFκB has been linked to aggressive phenotype, poor ...
In an exclusive Network World test, Cisco’s Catalyst 4948-10GE delivered record low latency and line-rate throughput. Coupled with innovative security mechanisms and an extensive list of switching and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results